Contraceptive Technology Update – May 1, 2016
May 1, 2016
View Issues
-
2 studies show monthly vaginal ring protects women against HIV
Results presented at the 2016 Conference on Retroviruses and Opportunistic Infections from two large Phase III clinical trials suggest that a monthly vaginal ring containing the antiretroviral drug dapivirine (and no contraceptives) can safely help prevent HIV-1 infection in women.
-
Food and Drug Administration takes steps to ensure safety of Essure
The Food and Drug Administration has taken steps to ensure the safety of the Essure method of permanent birth control. The agency has issued a new, mandatory clinical study to determine heightened risks for particular women.
-
Teen dating violence: Why you should screen
According to the Centers for Disease Control and Prevention, among high school students who date, 21% of females and 10% of males experience physical and/or sexual dating violence. -
Management of your patients’ menopause — Is your care on the right track?
By 2020, more than 50 million U.S. women will be older than 51, the mean age when menopause occurs. Despite the availability of effective hormonal and nonhormonal treatments for menopausal symptoms, few women with menopausal symptoms are evaluated or treated, reports a new scientific perspective.
-
Counsel your patients on their risk for pregnancies that are exposed to alcohol
The latest statistics from Centers for Disease Control and Prevention indicate that more than 3 million women between the ages of 15 and 44 are at risk of exposing their developing babies to alcohol because they are drinking and not using birth control to prevent pregnancy.1 The report also found that three in four women who want to get pregnant as soon as possible do not stop drinking alcohol when they stop using birth control.1
-
Access resource on LARC reimbursement
Obtain appropriate compensation for long-acting reversible contraceptive services with Intrauterine Devices and Implants: A Guide to Reimbursement, a new guide created by the American College of Obstetricians and Gynecologists’ long-acting reversible contraceptive Program, the National Health Law Program, the National Women’s Law Center, the National Family Planning and Reproductive Health Association, and the Bixby Center at the University of California, San Francisco.
-
Check coding for intrauterine devices
As of Jan. 1, 2016, the Centers for Medicare & Medicaid Services has discontinued use of HCPCS code J7302 for 52 mg levonorgestrel-releasing IUDs.